AstraZeneca plc -88.7% potential downside indicated by Barclays

AstraZeneca plc with ticker (LON:AZN) now has a potential downside of -88.7% according to Barclays.



Barclays set a target price of 1,350 GBX for the company, which when compared to the AstraZeneca plc share price of 11,950 GBX at opening today (14/04/2023) indicates a potential downside of -88.7%. Trading has ranged between 9,399 (52 week low) and 12,828 (52 week high) with an average of 1,785,580 shares exchanging hands daily. The market capitalisation at the time of writing is £183,927,173,159.

AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in various stages of clinical development. Its pipeline includes the Alexion Rare Disease portfolio and comprises approximately 179 projects. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include Farxiga, Lokelma, Crestor, Breztri and others. Its geographical segments include United Kingdom, Rest of Europe, The Americas and Asia, Africa & Australasia. It is also focused on discovering, developing, and manufacturing of T-cell receptor therapies.